# Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain

> **NCT00814021** · PHASE2 · COMPLETED · sponsor: **Institut Claudius Regaud** · enrollment: 21 (actual)

## Conditions studied

- Kidney Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** sunitinib malate

## Key facts

- **NCT ID:** NCT00814021
- **Lead sponsor:** Institut Claudius Regaud
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-12
- **Final completion:** 2011-03
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00814021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00814021, "Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00814021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*